IMNM logo

Immunome (IMNM) Company Overview

Profile

Full Name:

Immunome, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

October 2, 2020

Indexes:

Not included

Description:

IMNM (Immunome) is a biotechnology company focused on developing innovative therapies for cancer and infectious diseases. They use advanced technologies to discover and create immune-based treatments, aiming to improve patient outcomes and enhance the body's natural defense mechanisms against diseases.

Events Calendar

Earnings

Next earnings date:

Mar 28, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Nov 14, 24 Piper Sandler
Overweight
Nov 8, 24 Stephens & Co.
Overweight
Oct 25, 24 Wedbush
Outperform
Aug 13, 24 Wedbush
Outperform
Aug 13, 24 Piper Sandler
Overweight
May 31, 24 Piper Sandler
Overweight
Apr 30, 24 JP Morgan
Overweight
Apr 15, 24 Guggenheim
Buy
Apr 1, 24 Wedbush
Outperform
Jan 23, 24 Wedbush
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
IMNM
businesswire.comJanuary 31, 2025

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 22,258,064 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,903,225 shares, at a price to the public of $7.75 per share. The gross proceeds to Immunome from the offering, befo.

Immunome Announces Pricing of Upsized Public Offering of Common Stock
Immunome Announces Pricing of Upsized Public Offering of Common Stock
Immunome Announces Pricing of Upsized Public Offering of Common Stock
IMNM
businesswire.comJanuary 29, 2025

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 19,354,839 shares of its common stock at a price to the public of $7.75 per share. All of the shares are to be sold by Immunome. The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering ex.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IMNM
businesswire.comJanuary 2, 2025

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on January 2, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 45,000 shares of common stock to four new employees under the Company's 2024 Induc.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IMNM
businesswire.comDecember 2, 2024

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 2, 2024, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase 210,500 shares of common stock to 15 new employees under the Company's 2024 Inducement Plan. The.

Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates
Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates
Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates
IMNM
zacks.comNovember 13, 2024

Immunome, Inc. (IMNM) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.36 per share a year ago.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IMNM
businesswire.comNovember 1, 2024

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 31, 2024, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase 378,800 shares of common stock to 14 new employees under the Company's 2024 Inducement Plan. The.

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
IMNM
businesswire.comOctober 18, 2024

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster highlighting preclinical evaluation of IM-1021, a ROR1-targeted antibody drug conjugate (ADC), at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on October 24, 2024. Immunome expects to submit an IND for the IM-1021 program to the FDA in.

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
IMNM
businesswire.comAugust 29, 2024

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 5:35 P.M. Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations.

Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates
Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates
Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates
IMNM
zacks.comAugust 12, 2024

Immunome, Inc. (IMNM) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.46 per share a year ago.

Immunome: AL102 And Other Established Protein Targets Could Drive Value
Immunome: AL102 And Other Established Protein Targets Could Drive Value
Immunome: AL102 And Other Established Protein Targets Could Drive Value
IMNM
seekingalpha.comJune 27, 2024

Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021 is an antibody-drug conjugate being developed to target ROR1 expressing solid tumors; IND filing to begin a phase 1 study for this program, expected Q1 of 2025.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for Immunome?
  • Does Immunome pay dividends?
  • What sector is Immunome in?
  • What industry is Immunome in?
  • What country is Immunome based in?
  • When did Immunome go public?
  • Is Immunome in the S&P 500?
  • Is Immunome in the NASDAQ 100?
  • Is Immunome in the Dow Jones?
  • When was Immunome's last earnings report?
  • When does Immunome report earnings?
  • Should I buy Immunome stock now?

What is the ticker symbol for Immunome?

The ticker symbol for Immunome is NASDAQ:IMNM

Does Immunome pay dividends?

No, Immunome does not pay dividends

What sector is Immunome in?

Immunome is in the Healthcare sector

What industry is Immunome in?

Immunome is in the Biotechnology industry

What country is Immunome based in?

Immunome is headquartered in United States

When did Immunome go public?

Immunome's initial public offering (IPO) was on October 2, 2020

Is Immunome in the S&P 500?

No, Immunome is not included in the S&P 500 index

Is Immunome in the NASDAQ 100?

No, Immunome is not included in the NASDAQ 100 index

Is Immunome in the Dow Jones?

No, Immunome is not included in the Dow Jones index

When was Immunome's last earnings report?

Immunome's most recent earnings report was on Nov 13, 2024

When does Immunome report earnings?

The next expected earnings date for Immunome is Mar 28, 2025

Should I buy Immunome stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions